**Key Developments**: - Excellence RX (02687) launched its IPO from Nov 28 to Dec 3, offering 6.67M H shares globally. - Naxin Micro (02676) initiated its IPO during the same period, planning to issue 19.07M shares. - Sihuan Pharma (02005) secured regulatory approval for Tolterodine Tartrate Sustained-Release Capsules (4mg). - Innovent Biologics (01801): Sintilimab (Pikankizumab Injection) approved by NMPA for moderate-to-severe plaque psoriasis. - JIANGXI COPPER (00358) proposed acquiring shares in SolGold Plc, a foreign-listed company. - ZTO EXPRESS-W (02057) plans to acquire Zhejiang Xinglian for RMB178M to enhance cross-border air logistics capabilities. - China Shenhua (01088): Unit 3 of Beihai Phase II passed 168-hour trial operation and entered commercial service. - Shanghai Zhida Technology Development (02650) signed a RMB100M+ EV charging pile deal with Saudi Controls Ltd, expanding into the Middle East. - Hengdeli (03389) received a 12% premium voluntary cash offer from Junya, resuming trading on Dec 1. - Zijin Mining (02899) donated HKD20M to support post-fire reconstruction in Hong Kong’s Tai Po District. - Guoquan (02517) and Innoscience (02577) contributed HKD10M and HKD2M, respectively, for Tai Po fire relief.

**Operational Results**: - MEITUAN-W (03690) reported Q3 revenue of ~RMB95.5B (+2% YoY), highlighting flash delivery and global strategy. - CHINA GAS HOLD (00384) posted interim net profit of HKD1.33B, declaring an interim dividend of 15 HKD cents/share. - UNITY GP HLDGS (01539) achieved HKD27.5M interim profit (+35.68% YoY), with gross margin surging to 67.3%. - Guofu Quantum (00290) reported HKD1.03B interim revenue (+4564.52% YoY). - Yuhua Education (06169) annual adjusted net profit rose 95.6% to RMB914M. - China Water (00855) interim revenue reached HKD5.18B, with a dividend of 13 HKD cents/share. - Zhonghui Group (00382) annual revenue grew 7.7% to RMB2.49B.